Oncology

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

Featured

FDA Alert
FDA
FDA Alert
FDA Approves Relacorilant (Lifyorli) Plus Nab-Paclitaxel for Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
04/23/2026
Anthony Calabro, MA
On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...
04/23/2026
Pop Quiz
Stethoscope image
Pop Quiz
Prior Adenoma and Colorectal Cancer Risk in Older Adults
04/22/2026
Ashton L. Stahl
How much does a prior adenoma matter after age 75? Test your understanding of CRC risk vs competing mortality.
04/22/2026
Photoclinic
Initial plain radiograph
Photoclinic
Myxofibrous Tumor Progression to Osteosarcoma
04/22/2026
Kalyani N. Ballur, MD; Oluwaferanmi T. Dada, BS; Evan Maroun, MS; Kevin Pierre, MD; Troy Storey, MD; Diego A. L. Garcia, MD
A 67-year-old man, monitored since October 2022 for an incidental left proximal femoral lesion, arrived as a transfer from an outside hospital where he presented with an inability to walk after feeling a...
04/22/2026

Interactive Features

Pop Quiz
Stethoscope image
Pop Quiz
Prior Adenoma and Colorectal Cancer Risk in Older Adults
04/22/2026
Ashton L. Stahl
How much does a prior adenoma matter after age 75? Test your understanding of CRC risk vs competing mortality.
04/22/2026
Quiz Series
patient in hospital bed
Quiz Series
Evolving Patterns of Neoadjuvant Systemic Therapy in US Cancer Care
03/05/2026
Anthony Calabro, MA
Trends from the National Cancer Database show that the use of neoadjuvant systemic therapy (NST) has increased sharply over the past decade but not uniformly across cancer types or stages. Test your...
03/05/2026
Slideshow
doctor with headphones at her laptop
Slideshow
Top 5 Podcast Episodes of 2025
12/23/2025
Kate Young
This year we’ve explored critical clinical insights, cutting-edge care strategies, and expert perspectives on our podcast. Today, we’re excited to count down the five standout podcast episodes that...
12/23/2025
Pop Quiz
physician at desk
Pop Quiz
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
12/17/2025
Ashton L. Stahl
As researchers continue exploring early-intervention strategies for high-risk smoldering multiple myeloma, understanding the basic pathophysiology of plasma cell disorders (and the targets of emerging...
12/17/2025
Pop Quiz
man clutching heart
Pop Quiz
Recognizing Cardiovascular Risks with Ibrutinib
12/09/2025
Anthony Calabro, MA
Ibrutinib, the first-generation Bruton tyrosine kinase inhibitor, has well-documented cardiovascular effects that influence treatment decisions for patients with chronic lymphocytic leukemia. This quiz...
12/09/2025

Clinical Insights

Sponsored
Tim F. and Fadi Haddad, MD
Sponsored
Myelofibrosis Caregiver Interview Series: Monitoring Myelofibrosis Treatment Effectiveness
04/21/2026
Fadi G. Haddad, MD
Monitoring treatment response in myelofibrosis requires a balanced assessment of patient-reported symptoms, objective scoring tools, hematologic parameters, and spleen size. In part 1 of this Myelofibrosis...
04/21/2026
Video
Brian M. Slomovitz, MD
Video
Investigating Immunotherapy and Chemotherapy in Endometrial Cancer Outcomes
03/03/2026
Brian M. Slomovitz, MD
In this video, Brian M. Slomovitz, MD, discusses his recent study demonstrating a significant improvement in disease-free survival with pembrolizumab in patients with dMMR endometrial cancer. He explains...
03/03/2026
Expert Q&A
Brady L Stein, MD
Expert Q&A
How the ASH Clinical Practice Guidelines Aim to Improve Myelofibrosis Management
12/22/2025
Brady L. Stein, MD
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
12/22/2025
Expert Q&A
Daniel Lenihan, MD, FACC, FESC, FIC-OS
Expert Q&A
Multidisciplinary Management of Cardiovascular Risk in Patients With CLL on BTK Inhibitors
11/04/2025
Daniel Lenihan, MD, FACC, FESC
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
11/04/2025
Video: Multidisciplinary Roundtable
Jaspal Singh, MD, MHA, MHS
Video: Multidisciplinary Roundtable
Incidental Lung Nodule Programs: The Tip of the Iceberg for Pulmonary Practices
08/25/2025
Jaspal Singh, MD, MHA, MHS; Jasleen Pannu, MD; Coral Giovacchini, MD; Leisa Lackey
In this video roundtable discussion, Jaspal Singh, MD, MHA, MHS, interviews Jasleen Pannu, MD, Coral Giovacchini, MD, and Leisa Lackey about the design, growth, and importance of incidental lung nodule...
08/25/2025